Guidance Point Advisors LLC Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Guidance Point Advisors LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 6.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,751 shares of the company’s stock after selling 117 shares during the period. Guidance Point Advisors LLC’s holdings in Johnson & Johnson were worth $253,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in JNJ. Norges Bank acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $4,390,037,000. Raymond James Financial Inc. purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $1,339,878,000. Vanguard Group Inc. boosted its stake in Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company’s stock worth $33,666,460,000 after buying an additional 1,772,706 shares during the period. Franklin Resources Inc. increased its position in shares of Johnson & Johnson by 11.4% during the third quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock valued at $2,721,355,000 after acquiring an additional 1,729,281 shares during the last quarter. Finally, Amundi raised its stake in shares of Johnson & Johnson by 16.2% in the 4th quarter. Amundi now owns 11,930,183 shares of the company’s stock valued at $1,698,984,000 after acquiring an additional 1,660,458 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.4 %

Johnson & Johnson stock opened at $155.41 on Thursday. The stock’s fifty day moving average is $159.36 and its two-hundred day moving average is $155.98. The stock has a market cap of $374.51 billion, a PE ratio of 23.37, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.29 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Raymond James lowered their price target on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday. Leerink Partners lowered their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Bank of America lifted their target price on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.